en Immunotherapy and Targeted Therapies Review Article <div style="text-align: justify;"><span style="font-size:11pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">The Importance of Study</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">: Ovarian cancer remains a major global oncological burden due to its late-stage diagnosis and high mortality. Despite progress in surgery, chemotherapy, and targeted therapies, patient outcomes are often hindered by recurrence and chemoresistance. Early detection remains inadequate, emphasizing the need for innovative treatments. </span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">Methods</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">: Targeted nanotherapeutics offer a promising approach by enabling precise drug delivery through nanoscale carriers that enhance solubility, bioavailability, and tumor-specific accumulation while reducing systemic toxicity. </span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">Results</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">: Nanoscale drug carriers demonstrated enhanced bioavailability, with preferential tumor accumulation leading to improved therapeutic efficacy. </span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">Conclusions</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">: This review summarizes the current challenges in ovarian cancer management and highlights the potential of targeted nanodelivery systems to improve therapeutic efficacy and survival through controlled, cancer-specific drug-release mechanisms</span></span></span><span style="font-size:10.5pt"><span style="line-height:120%"><span style="color:#231f20">.</span></span></span><span style="font-size:10.5pt"><span style="line-height:120%"></span></span></span></span></span></div> Ovarian Cancer, Nanotherapeutics, Targeted Drug Delivery, Smart Delivery Systems, Active Targeting 6 10 http://mcijournal.com/browse.php?a_code=A-10-715-1&slc_lang=en&sid=1 moluk Aivazi apadanaaivazi1399@gmail.com 10031947532846004318 0009000238031382 Yes Department of Biomedical Engineering, Apadana Institute of Higher Education, Shiraz, Iran